Clinical Trial

HAIC Plus Systemic Chemotherapy, Lenvatinib and Toripalimab in Advanced ICC

Completed Phase 2
View on ClinicalTrials.gov →
Summary
Prognosis for unresectable intrahepatic cholangiocarcinoma (ICC) remains poor. Treatment combination known as Gemox (systemic chemotherapy of gemcitabine and oxaliplatin), along with lenvatinib and toripalimab, has shown favor results for ICC patients. However, Hepatic Arterial Infusion Chemotherapy (HAIC), which delivers chemotherapy directly to the liver, has also demonstrated benefits in controlling the cancer locally and improving survival for patients with ICC. Based on these promising approaches, this study aims to find out if adding HAIC to the systemic chemotherapy-based treatment can help extending patients survival.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-24.
Trial Details
NCT Number NCT07304388
Lead Sponsor Sun Yat-sen University
Conditions Intrahepatic Cholangiocarcinoma (Icc)
Enrollment 96 participants
Start Date 2023-02-10
Primary Completion 2025-04-01 (estimated)
Study Completion 2025-06-01 (estimated)
Updated on ClinicalTrials.gov 2025-12-30